The therapeutic efficacy of propranolol in children with recurrent primary epistaxis

• Main Authors: Bjelakovic B (Author), Bojanovic M (Author), Lukic S (Author), Saranac L (Author), Vukomanovic V (Author), Prijic S (Author), Zivkovic N (Author), Randjelovic D (Author)
• Format: Knjiga
• Izdano: Dove Medical Press, 2013-03-01T00:00:00Z.
• Teme: article
• Online dostop: Connect to this object online.
• Notes: 1177-8881
• Keywords: Therapeutics. Pharmacology; RM1-950
• Source: Drug Design, Development and Therapy, Vol 2013, Iss default, Pp 127-129 (2013)

Bojko Bjelakovic,1,2 Mila Bojanovic,2,3 Stevo Lukic,2,4 Ljiljana Saranac,1,2 Vladislav Vukomanovic,5,6 Sergej Prijic,5 Nikola Zivkovic,7 Dusica Randjelovic11Clinic of Pediatrics, Clinical Center, Nis, Serbia; 2Faculty of Medicine, University of Nis, Nis, Serbia; 3Clinic of Otorhinolaryngology, Clinical Center, Nis, Serbia; 4Clinic of Neurology, Clinical Center, Nis, Serbia; 5Mother and Child Health Institute, "Dr Vukan Cupic", Belgrade, Serbia; 6Faculty of Medicine, University of Belgrade, Serbia; 7Institute of Pathology, Faculty of Medicine, University of Nis, Nis, SerbiaAbstract: We hypothesized that some characteristics of beta-blockers, including negative inotropic, peripheral vasoconstrictor, and antiangiogenic effects, might be potentially useful in treating children with epistaxis. From June 2010 to March 2012, a total of seven children with recurrent primary epistaxis resistant to conventional management were observed at our institution. An overall effectiveness of propranolol was noted in all seven children when given a dose of 1.5–2 mg/kg/day (divided into three doses) as a second line therapy for terminating epistaxis. Based on our first experience, we believe that propranolol could be a favorable treatment option for patients with primary epistaxis.Keywords: beta-blocker, epistaxis, children